SCHEMBL3698235

SCHEMBL3698235

CC(C)=NNc1ccc(C(=O)ON2C(=O)CCC2=O)cn1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.38
RAB9A P51151 3/20 0.36
GAA P10253 2/20 0.36
MAPT P10636 2/20 0.36
NPC1 O15118 1/20 0.36
HCAR3 P49019 4/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
NNMT P40261 1/20 0.35
GRM5 P41594 2/20 0.34
VNN1 O95497 3/20 0.34
KDM4E B2RXH2 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
POLB P06746 1/20 0.34
GFER P55789 1/20 0.34
CRBN Q96SW2 2/20 0.33
MGLL Q99685 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetone SCHEMBL1019109 0.82 MAPK1 (0.40) MAPK1RAB9AGAAMAPTNPC1
SCHEMBL14418820 0.82 ALDH1A1 (0.42) MAPK1RAB9AGAAMAPTNPC1
SCHEMBL1509187 0.81 MAPK1 (0.41) MAPK1RAB9ANPC1HCAR3NNMT
Acetone SCHEMBL17732269 0.81 MAPK1 (0.39) MAPK1RAB9AGAANPC1HCAR3
SCHEMBL1445644 0.80 MAPK1 (0.40) MAPK1RAB9AGAAHCAR3NNMT
SCHEMBL30914672 0.80 MAPK1 (0.40) MAPK1RAB9AGAAHCAR3NNMT
Hydrochloric Acid SCHEMBL5087052 0.80 MAPK1 (0.40) MAPK1RAB9AHCAR3NNMTGRM5
SCHEMBL14181985 0.80 NAMPT (0.38) MAPK1RAB9ANPC1KDM4E
Hydrochloric Acid SCHEMBL310253 0.79 MAPK1 (0.39) MAPK1RAB9AGAAHCAR3NNMT
Hydrochloric Acid SCHEMBL30019344 0.79 MAPK1 (0.39) MAPK1RAB9AGAAHCAR3NNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111505264-B Exosome separation method, immunomagnetic beads and kit 上海思路迪生物医学科技有限公司 2024-05-17 CN disclosed
US-11747279-B2 Optical biomodule for detection of diseases at an early onset MAZED MOHAMMAD A (US) 2023-09-05 US disclosed
US-11747279-B2 Optical biomodule for detection of diseases at an early onset MAZED MOHAMMAD A (US) 2023-09-05 US disclosed
US-11320588-B1 Super system on chip MAZED MOHAMMAD A (US) 2022-05-03 US disclosed
US-20220003676-A1 Optical biomodule for detection of diseases at an early onset MAZED MOHAMMAD A (US) 2022-01-06 US disclosed
US-20210325376-A1 POLYMERS AND CONJUGATES COMPRISING THE SAME VENTANA MED SYST INC (US) 2021-10-21 US disclosed
US-11079372-B2 Polymers and conjugates comprising the same VENTANA MEDICAL SYSTEMS, INC. (US) 2021-08-03 US disclosed
CN-106432504-B E-Cadherin, Cadherin-11 and EpCAM multiple antibody immunomagnetic beads and preparation method thereof 上海美吉生物医药科技有限公司 2021-03-30 CN disclosed
CN-106279420-B CD20 antibody immunomagnetic beads and preparation method thereof 上海美吉生物医药科技有限公司 2021-03-30 CN disclosed
CN-106279422-B HER2 antibody immunomagnetic bead and preparation method thereof 上海美吉生物医药科技有限公司 2021-03-30 CN disclosed
WO-2013178236-A1 CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) 2013-12-05 WO disclosed
WO-2013139803-A1 CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2013-09-26 WO disclosed
US-20130052731-A1 HUMANIZED LEWIS-Y SPECIFIC ANTIBODY-BASED DELIVERY OF DICER SUBSTRATE siRNA (D-siRNA) AGAINST STAT3 MA YUELOG (US) 2013-02-28 US disclosed
US-20120121641-A1 MHC OLIGOMER AND METHOD OF MAKING THE SAME PROIMMUNE LIMITED (GB) 2012-05-17 US disclosed
EP-1844072-B1 MHC OLIGOMER AND METHOD OF MAKING THE SAME PROIMMUNE LTD (GB) 2012-04-04 EP disclosed
US-20100292183-A1 TETRACYCLINE AND USES THEREOF PLAXGEN, INC. 2010-11-18 US disclosed
US-20100292183-A1 TETRACYCLINE AND USES THEREOF PLAXGEN, INC. 2010-11-18 US disclosed
US-20080207485-A1 Mhc Oligomer And Method Of Making The Same PROIMMUNE LIMITED 2008-08-28 US disclosed
EP-1844072-A1 MHC OLIGOMER AND METHOD OF MAKING THE SAME ProImmune Limited (GB) 2007-10-17 EP disclosed
WO-2006082387-A1 MHC OLIGOMER AND METHOD OF MAKING THE SAME PROIMMUNE LIMITED (GB) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121641-A1 MHC OLIGOMER AND METHOD OF MAKING THE SAME MICA, HLA-DRB1, CD74 MAPK1 4678/4885RAB9A 3867/4885GAA 2390/4885
US-20130052731-A1 HUMANIZED LEWIS-Y SPECIFIC ANTIBODY-BASED DELIVERY OF DICER SUBSTRATE siRNA (D-siRNA) AGAINST STAT3 AGO2, HNRNPH3, HCLS1 MAPK1 3537/4885RAB9A 62/4885GAA 3215/4885
US-20080207485-A1 Mhc Oligomer And Method Of Making The Same MICA, HLA-DRB1, CD74 MAPK1 4665/4885RAB9A 3784/4885GAA 2362/4885
US-20100292183-A1 TETRACYCLINE AND USES THEREOF TET1, TET3, TNNT2 MAPK1 4509/4885RAB9A 3330/4885GAA 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.